Condition: Metastatic Triple Negative Breast Cancer or Metastatic Testicular Cancer, or Stage II-IV Diffuse Large B Cell Lymphoma

Study Type: Interventional

Clinical Trials Identifier NCT 8-digits: NCT07258563

Sponsor: University Medical Center Groningen

Eligibility:

• Age: minimum 18 Years maximum 70 Years
• Gender: All

Inclusion Criteria:

• Age ≥18 and ≤70 years
• Indication to start chemotherapy for:
• Metastatic triple negative breast cancer
• Metastatic testicular cancer
• Stage II-IV diffuse large B cell lymphoma
• Chemotherapy scheduled to start in the next 6 weeks
• Consuming solid foods and drinks is possible
• ≤50% of recommended daily intake in kcal consists of oral nutritional supplements
• Oral mucositis grade ≤2 (Common Terminology Criteria for Adverse Events, version 5.0)
• Ability to comply with all protocol-required actions
• Written informed consent
• For the intervention phase only: subjective change in taste since start of chemotherapy

Exclusion Criteria:

• Pregnancy
• Currently experiencing taste or smell problems
• Previous or current radiotherapy of head and neck region
• Enteral feeding through tube or parenteral feeding
• Participation in another clinical trial aimed at preventing or treating taste and/or smell alterations
• Chronic (>1 month) high dose corticosteroids (>10 mg prednisone/day or equivalent).

View trial on ClinicalTrials.gov